With the PDUFA date for Johnson & Johnson's (NYSE:JNJ) SGLT-2 inhibitor Invokana just around the corner, the FDA will soon deliberate on another Type 2 diabetes drug that belongs to the same class: Eli Lilly's (NYSE:LLY) empagliflozin. Can these drugs get the green light, or will the FDA require both companies to run more clinical trials? Is the FDA's rejection of Forxiga, an SGLT-2 inhibitor developed by Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN) a signal that these drugs will face an uphill battle during the approval process? Health-care analyst Max Macaluso discusses these topics in the following video.
- Mar 25, 2013 at 7:30PM
- Health Care